2000 Alameda de las Pulgas, suite 120
166 articles with Innovent Biologics
Innovent Releases Results of a Phase 3 Clinical Study of Tafolecimab（IBI306）in Chinese Patients with non- Familial Hypercholesterolemia at the American Heart Association (AHA) Scirntific Sessions 2022
Innovent Biologics, Inc. announces that the results of a phase 3 clinical study of tafolecimab, a recombinant fully human anti-PCSK-9 monoclonal antibody, in Chinese patients with non-familial hypercholesterolemia were presented at the American Heart Association Scientific Sessions 2022 as an e-poster.
Innovent Announces First Patient Dosing in Australia in Phase I Study of IBI343 (Recombinant anti-Claudin18.2 Monoclonal Antibody-drug Conjugate) in Patients with Advanced Solid Tumors
Innovent Biologics, Inc. announced that the first patient was dosed in Australia for its proprietary anti-Claudin18.2 monoclonal antibody-drug conjugate in Phase I clinical trial for the treatment of patients with advanced solid tumors.
Innovent Announces Phase Ib Results of Higher-dose Mazdutide (IBI362) in Chinese Participants with Overweight or Obesity Published in eClinicalMedicine
Innovent Biologics, Inc. announced that results of higher-dose cohorts in a phase 1b study of mazdutide (IBI362), a glucagon-like peptide-1 (GLP-1) and glucagon receptor dual agonist, in Chinese participants with overweight or obesity have been published online in eClinicalMedicine
The China NMPA Approves Selpercatinib for the Treatment of Patients with RET-driven Lung and Thyroid Cancers
Innovent Biologics, Inc. is pleased to see that the NMPA of China has approved the NDA for selpercatinib for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with a rearranged during transfection gene fusion, adult and pediatric patients 12 years of age and older with advanced or metastatic medullary thyroid cancer with a RET mutation who require systemic therapy.
The China NMPA Approved CYRAMZA® (ramucirumab) for the Treatment in Patients with Hepatocellular Carcinoma
Innovent Biologics, Inc. is pleased to see that the National Medical Products Administration of China has approved the supplemental New Drug Application for CYRAMZA® in patients with hepatocellular carcinoma, who have an alpha fetoprotein of ≥400 ng/mL and have been treated with sorafenib.
Innovent's Sintilimab plus Chemotherapy Demonstrated PFS Benefit in Patients with EGFR-mutated Non-Squamous Non-Small Cell Lung Cancer in the Second Interim Analysis Results of the ORIENT-31 Study
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801) announced second interim analysis results of the randomized, double-blinded, multi-center Phase 3 ORIENT-31 study (NCT03802240) conducted in China evaluating sintilimab with or without anti-VEGF antibody therapy.
Innovent Announces First Participant Dosed in the Higher-dose Cohort of a Phase 2 Clinical Trial of Mazdutide in Chinese Adults with Obesity
Innovent Biologics, Inc. announces that the first participant has been successfully dosed in the higher-dose cohort of a phase 2 clinical trial of mazdutide, a glucagon-like peptide 1 receptor and glucagon receptor dual agonist, in Chinese adults with obesity.
Innovent Announced 2022 Interim Results and Business Updates
Innovent Biologics, Inc. announced 2022 interim results and major company updates.
Innovent Announces First Subject Dosed in Phase 1 Study of IBI311 (Anti-IGF-1R Monoclonal Antibody)
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and other major diseases, announces that the first healthy volunteer has been successfully dosed in the Phase 1 study of IBI311.
Amgen announced two lung cancer studies with mixed results, Innovent dosed the first patient in a Phase I diabetic macular edema study and HUTCHMED hit the primary endpoint in colorectal cancer.
Innovent Announces Phase 2 Clinical Study of Picankibart (IBI112) in Chinese Patients with Moderate-to-severe Plaque Psoriasis Met Primary Endpoint
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), announces that the primary endpoint was met in a multicenter, randomized, double-blind, placebo-controlled phase 2 study (clinicaltrials.gov, NCT 05003531) of picankibart (R&D code: IBI112), a recombinant anti-interleukin 23p19 subunit antibody injection, in Chinese patients with moderate-to-severe plaque psoriasis.
Innovent Announces First Patient Dosed in Phase 1 Study of IBI324 (VEGF-A/Ang-2 Bispecific Antibody) in Patients with Diabetic Macular Edema
Innovent Biologics, Inc. announces that the first patient with diabetic macular edema has been successfully dosed in the Phase 1 study of IBI324, a potential first-in-class ophthalmic recombinant human anti-VEGF-A and anti-Ang-2 bispecific antibody.
The agreement will grant Innovent exclusive development and marketing rights to tusamitamab in China, while Sanofi will be entitled to up to $81 million in milestones and royalties.
Innovent Biologics and Sanofi Enter Strategic Collaboration to Accelerate Development of Oncology Medicines and Expand Presence in China
Innovent Biologics, Inc. ("Innovent", HKEX: 01801), and Sanofi announced a collaboration to bring innovative medicines to patients in China with difficult-to-treat cancers.
Press Release: Sanofi and Innovent Biologics enter strategic collaboration to accelerate development of oncology medicines and expand presence in China
Sanofi and Innovent Biologics announced a collaboration to bring innovative medicines to patients in China with difficult-to-treat cancers.
Innovent and Laekna Jointly Announce First Patient Dosed with Three-drug Combination in a Phase 1/2 Study for the Treatment of Patients with Solid Tumors Who Were Resistant to Prior Anti-PD-1/PD-L1 Therapy
Innovent Biologics, Inc. and Laekna Therapeutics jointly announced that the first patient has been dosed in a Phase 1/2 clinical trial of a three-drug combination therapy in patients with specific solid tumors who were resistant to anti-PD-1/PD-L1 therapy at the West China Second Hospital of Sichuan University.
Innovent Biologics' Phase II trial of mazdutide, a potential treatment for type 2 diabetes, showed the drug met its primary endpoint by successfully reducing HbA1c levels.
Innovent and Ascentage Pharma Announce the China NMPA Accepted and Granted Priority Review Designation to a New Drug Application for Olverembatinib for the Treatment of Drug-Resistant CML
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), and Ascentage Pharma (6855.HK), today announce that the Center for Drug Evaluation (CDE) of China National Medical Products Administration (NMPA) has accepted and granted Priority Review designation.
Significant Glycemic Control and Weight Loss: Innovent Announces Phase 2 Study of Mazdutide (IBI362) in Chinese Patients with Type 2 Diabetes Met Primary Endpoint
Innovent Biologics, Inc. (Innovent) (HKEX: 01801), announces that the primary endpoint was met in a multi-center, randomized, double-blind, placebo and dulaglutide-controlled phase 2 study of mazdutide (R&D code: IBI362), a glucagon-like peptide-1 receptor (GLP-1R) and glucagon receptor (GCGR) dual agonist, in Chinese patients with type 2 diabetes.
Innovent Announces First Patient Dosed in a Phase 2 Clinical study of IBI112 (IL-23p19 Monoclonal Antibody) in Patients with Moderate-to-Severe Active Ulcerative Colitis
Innovent Biologics, Inc. announced that the first patient with moderate-to-severe active ulcerative colitis has been successfully dosed in a Phase 2 clinical study of its innovative recombinant anti-interleukin 23p19 subunit antibody injection in China.